Common TitleBLQ Study
Official Title A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients
Phase Phase IV
ClinicalTrials.gov NCT00326963
Treatments
Enfuvirtide
Enfuvirtide
Tradename:FuzeonOther Names:T-20Class:Entry InhibitorsCategories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryHoffmann-La Roche
References
- DeJesus E, Gottlieb MS, Gathe JC Jr, Greenberg ML, Guittari CJ, Zolopa AR. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. Antimicrob Agents Chemother. 2008;52:4315-9.